Alnylam Pharmaceuticals, Inc. (ALNY)

Alnylam Pharmaceuticals, Inc. (ALNY) is a healthcare company (biotechnology) based in the United States. The share price is $156.93, down 1.75% on the day, which values the company at $21.02B. Price as of 17 Nov 2026, 17:42 UTC, from Yahoo Finance.

Key facts

Share price
$156.93−1.75% today
Market value
$21.02B
P/E ratio
7.9×last 12 months
Forward P/E
14.5×
Funk Score
71/100
Against its own history
Well below its usual priceusual price $428.08
200-week average
$257.3839% below
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Alnylam Pharmaceuticals, Inc. in more detail

ALNY trades at 7.9× its last twelve months' earnings, 14.5× next year's expected earnings, 4.2× sales. Measured against its own history, the price is 63% below what its usual multiples would imply ($428.08) — well below its usual price. It sits 39% below its 200-week average of $257.38.

Over the last five fiscal years Alnylam Pharmaceuticals, Inc. has compounded revenue 49.8% a year. Its Funk Score is 71 out of 100 (financial strength 5.6, profitability 5.3, growth 10.0, value 7.6, each out of 10).

In its favour: Operating margin is expanding; Five straight years of revenue growth. Worth checking: Share count keeps rising; Thin interest cover.

4 of the superinvestors tracked here hold ALNY, including Baillie Gifford team (1.3% of the portfolio), Dodge & Cox team (0.3% of the portfolio), David Shaw (founder) (0.2% of the portfolio).

Superinvestors holding ALNY

4 of the investors tracked here report a position in their latest 13F filing.

Compare

Health Care companies of similar size

Side by side:ALNY vs ZBH (Alnylam Pharmaceuticals, Inc. vs Zimmer Biomet Holdings)ALNY vs GH (Alnylam Pharmaceuticals, Inc. vs Guardant Health)ALNY vs BNTX (Alnylam Pharmaceuticals, Inc. vs BioNTech)ALNY vs MEDP (Alnylam Pharmaceuticals, Inc. vs Medpace Holdings)ALNY vs THC (Alnylam Pharmaceuticals, Inc. vs Tenet Healthcare)

All health care companies by market valueLargest companies in the United StatesAll stocks A–Z

Alnylam Pharmaceuticals, Inc. (ALNY): questions and answers

What is ALNY's P/E ratio?

Alnylam Pharmaceuticals, Inc. trades at 7.9× its last twelve months' earnings and 14.5× next year's expected earnings.

What is ALNY's PEG ratio?

Alnylam Pharmaceuticals, Inc.'s PEG ratio is 0.22 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.

What is Alnylam Pharmaceuticals, Inc.'s market cap?

Alnylam Pharmaceuticals, Inc. is valued at $21.02B at a share price of $156.93.

Is ALNY overvalued or undervalued?

Against its own history, ALNY is well below its usual price: the price is 63% below the $428.08 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is ALNY above its 200-week moving average?

No. ALNY is 39.0% below its 200-week average of $257.38. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is Alnylam Pharmaceuticals, Inc. growing?

Over the last five fiscal years Alnylam Pharmaceuticals, Inc.'s revenue grew 49.8% a year.

Cite this page

Funkfolio, “Alnylam Pharmaceuticals, Inc. (ALNY) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/ALNY

Underlying data: Yahoo Finance; company filings with the SEC.